Insulin-induced localized lipoatrophy

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 22, Issue 4, 2013, Pages 83-85

  Breznik, Vesna ^a   Kokol, Rok ^b   Luzar, Boštjan ^c   Miljković, Jovan ^b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY OF MARIBOR   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL WALL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; LIPODYSTROPHY; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84894501638     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10162-012-0041-0     Document Type: Article

References (16)

1. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol. 2003;4:661-7.
2. Mokta JK, Mokta KK, Panda P. Insulin lipodystrophy and lipohypertrophy. Indian J Endocrinol Metab. 2013;17:773-4.
3. Radermecker RP, Pierard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8:21-8.
4. Atlan-Gepner C, Bongrand P, Farnarier C, et al. Insulin-induced lipoatrophy in type 1 diabetes. A possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care. 1996;19:1283-5.
5. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes care. 1993;16(Suppl 3):155-65.
6. Sackey AH. Injection-site lipoatrophy. N Engl J Med. 2009;361;e41.
7. Holstein A, Sterge H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf. 2010;9:225-31.
8. Chantelau EA, Praetor R, Praetor J, Poll LW. Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report. Diabetology & Metabolic Syndrome. 2011;3:33.
9. Lopez X, Castells M, Ricker A, Velazquez EF, Mun E, Goldfine AB. Human insulin analog-induced lipoatrophy. Diab Care. 2008;31:442-4.
10. DeGroot AC. Is lipoatrophia semicircularis induced by pressure? Br J Dermatol. 1994;131:887-90.
11. Buyukgebiz A, Aydin A, Dunlar B. Localized lipoatrophy due to recombinant growth hormone therapy in a child with 6,7 kilobase gene deletion isolated growth hormone deficiency. J Pediatr Endocrinol Metab. 1999;12:85-7.
12. Dahl PR, Zalla MJ, Winkelmann RK. Localized involutional lipoatrophy: a clinicopathologic study of 16 patients. J Am Acad Dermatol. 1996;35:523-8.
13. Yamamoto T, Yokozeki H, Nishioka K. Localized involutional lipoatrophy: report of six cases. J Dermatol. 2002;29:638-43.
14. Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Brit Med J. 1980;1500-3.
15. Zalla MJ, Winkelmann RK, Gluck OS. Involutional lipoatrophy: macrophage-related involution of fat lobules. Dermatology. 1995;191:149-53.
16. Sasaki T, Kanbara T, Inayama Y. Do mucin-phagocytosing histiocytes in localized lipoatrophy have any primary pathogenic importance? Br J Dermatol. 1999;140:976-8.